Tsunami of immunotherapy reaches mesothelioma

Table 2 Recently published practice changing phase 3 studies in Malignant Pleural Mesothelioma

Clinical trial (Phase)	Population	Treatment arms	mOS		mPFS		AEs G3
CheckMate 743 (Phase III)[35]	Untreated MPM	Nivolumab 3 mg/kg every 2 wk + ipilimumab 1 mg/kg every 6 wk	18.1 mo	HR: 0.74, P = 0.002	6.8 mo	HR: 1.00	30%
		Cisplatin + pemetrexed	14.1 mo		7.6 mo		32%
CONFIRM (Phase III)[29]	Relapsed MPM	Nivolumab 3 mg/kg every 2 wk	9.2 mo	HR: 0.72, P = 0.002	3 mo	HR: 0.61; P < 0.001	19%
		Placebo	6.6 mo		1.8 mo		6.3%

MPM: Malignant pleural mesothelioma; MM: Malignant mesothelioma (pleural or peritoneal); AEs: Adverse events; mOS: Median overall survival; mPFS: Median progression free survival; G: Grade; HR: Hazard ratio.